




PROLONGED YOUTH INDEX

senev





There is currently an unprecedented convergence of breakthroughs in biotechnology that is yielding results targeting the fundamental biological processes of aging itself. Rather than merely treating age-related diseases after they emerge, a new generation of companies is developing therapies to prevent, slow, and even reverse core aging mechanisms: with breakthroughs in areas such as cellular senescence, epigenetic drift, mitochondrial decline, and loss of regenerative capacity.


This shift toward prolonged youthfulness provides a transformative investment opportunity.

The Prolonged Youth Index specifically targets upstream rejuvenation technologies with the potential to extend healthy human lifespan and maintain youthful biological function.

This focus represents a key differentiation from traditional aging-population ETFs which focus on senior care, nursing homes, and late-stage disease treatment. The Index focuses on rejuvenation platforms, regenerative and gene therapies, and enabling technologies.



INVESTMENT CASE





The global longevity sector stands at the intersection of powerful demographic tailwinds and accelerating scientific breakthroughs. The world's population aged 60+ is projected to grow from approximately 1 billion in 2020 to 2.1 billion by 20 [1].

At the same time, the longevity biotech market - focused on therapies that target the underlying mechanisms of aging - is expanding. Estimates place the current market size between \$23–31 billion in 2025/2026, with projections ranging from \$35 billion to over \$67 billion by 2030–2035, a CAGR of 8–10.7% [2,3].

Investor interest has followed this momentum. Longevity-focused companies raised approximately \$8.5 billion in 2024 reflecting growing confidence in platforms targeting cellular reprogramming, senolytics, and other hallmarks of aging [4].

Unlike traditional “aging population” investment themes that emphasize downstream healthcare services and late-stage disease treatment, the upstream rejuvenation market remains significantly under-represented in public markets. Most dedicated longevity science still resides in private companies or early clinical-stage public entities. The Prolonged Youth Index provides early diversified exposure and is placed to capture increased public markets attention to this theme.





[1] <https://www.who.int/news-room/fact-sheets/detail/ageing-and-health>

[2] https://www.researchandmarkets.com/reports/6226337/longevity-biotech-market-report?srsItid=AfmBOoqaWscp_AEJr5QcU4MzQwqNde4turPO1X-zFEWozSYfk1g7WNzn

[3] <https://www.snsinsider.com/reports/longevity-market-10022>


[4] <https://www.longevityinvestors.ch/post/the-global-longevity-investment-landscape-leading-investors-by-deal-count>





PERFORMANCE

Cumulative index performance




Index live date July 3, 2026

Index risk and return characteristics

Jul 04, 2026

	STD DEV(ANN %)	MAX DRAWDOWN %	DRAWDOWN PERIOD	SHARPE RATIO	SORTINO RATIO
INDEX	37.34	72.29	2021-02-08 - 2025-04-08	0.34	0.52
SPY	16.81	33.72	2020-02-19 - 2020-03-23	0.84	1.01
ACWI	16.97	33.53	2020-02-12 - 2020-03-23	0.61	0.74

Calendar year returns




	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
INDEX	59.86	26.96	6.72	-24.89	68.64	-8.72	26.5	112.09	-21.63	-40.89	13.53	2.71	0.03
SPY	13.81	13.47	1.23	12.0	21.7	-4.57	31.23	18.33	28.73	-18.65	26.18	24.89	17.72
ACWI	14.69	3.84	-2.2	8.41	24.33	-9.11	26.6	16.33	18.68	-18.82	22.29	17.45	22.41

Index Performance

	3MO %	YTD %	1YR %	3YR (ANN %)	5YR (ANN %)	10YR (ANN %)	ITD (ANN %)
INDEX	14.9	26.35	42.88	8.64	-9.15	10.36	12.66
SPY	13.32	9.8	20.42	20.42	12.95	15.36	14.09
ACWI	12.14	11.08	22.15	19.72	10.8	12.93	10.3

INVESTING IN THE INDEX



The Prolonged Youth Index is available as an SMA strategy via direct indexing for investors with Global Beta Advisors.



RIAs can access the Index via the Artha portfolio management platform, which is also accessible to advisors using the Nitrogen platform.





Index performance does not reflect the deduction of any fees or expenses. Performance is provided on a total-return basis. Historical performance illustrations in the indices may be based on a back-test calculation. Past performance of an index is not a guarantee of future results. This information does not constitute, and should not be considered a substitute for financial, legal, or tax advice

senev.com